NASDAQ:APTO - Aptose Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.29
  • Forecasted Upside: 79.71 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$6.28
▲ +0.15 (2.45%)
1 month | 3 months | 12 months
Get New Aptose Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APTO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.29
▲ +79.71% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aptose Biosciences in the last 3 months. The average price target is $11.29, with a high forecast of $16.00 and a low forecast of $9.00. The average price target represents a 79.71% upside from the last price of $6.28.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Aptose Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2020Canaccord GenuityReiterated RatingBuy$13.00High
i
10/19/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00High
i
Rating by A. Young at Cantor Fitzgerald
9/22/2020Alliance Global PartnersInitiated CoverageBuy$12.00High
i
6/23/2020Piper SandlerReiterated RatingOverweight$10.00High
i
6/14/2020OppenheimerInitiated CoverageBuy$9.00High
i
Rating by Matthew Biegler at Oppenheimer Holdings Inc.
6/12/2020Maxim GroupInitiated CoverageBuy$16.00High
i
6/12/2020HC WainwrightReiterated RatingBuy$9.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
4/27/2020HC WainwrightReiterated RatingBuy$9.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
3/4/2020Canaccord GenuityReiterated RatingBuy$13.00High
i
2/20/2020Maxim GroupInitiated CoverageBuy$16.00High
i
2/6/2020HC WainwrightBoost Price TargetBuy$6.00 ➝ $9.00Low
i
1/9/2020Piper SandlerInitiated CoverageOverweight$10.00High
i
8/7/2019HC WainwrightLower Price TargetBuy$8.50 ➝ $6.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/23/2019Roth CapitalReiterated RatingBuyHigh
i
Rating by J. Isaacson at Roth Capital
4/2/2019HC WainwrightSet Price TargetBuy$9.00Low
i
Rating by Joseph Pantginis at HC Wainwright
3/22/2019HC WainwrightSet Price TargetBuy$9.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
3/1/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$6.00Medium
i
1/25/2019CitigroupInitiated CoverageOutperform$6.00High
i
1/24/2019OppenheimerInitiated CoverageOutperform$6.00 ➝ $6.00High
i
12/13/2018HC WainwrightSet Price TargetBuy$9.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/12/2018Roth CapitalReiterated RatingBuyHigh
i
Rating by Jotin Marango at Roth Capital
12/3/2018HC WainwrightSet Price TargetBuy$9.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
11/26/2018HC WainwrightSet Price TargetBuy$9.00High
i
Rating by Joseph Pantginis at HC Wainwright
11/16/2018B. RileyInitiated CoverageBuy ➝ Buy$5.00High
i
Rating by G. Zavoico at B. Riley
11/7/2018HC WainwrightSet Price TargetBuy$9.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
10/10/2018HC WainwrightSet Price TargetBuy$9.00Low
i
Rating by Joseph Pantginis at HC Wainwright
8/8/2018HC WainwrightReiterated RatingBuy$9.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
6/29/2018HC WainwrightReiterated RatingBuy$8.50Low
i
Rating by Joseph Pantginis at HC Wainwright
5/13/2018HC WainwrightSet Price TargetBuy$6.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
5/7/2018HC WainwrightSet Price TargetBuy$6.00Low
i
Rating by Joseph Pantginis at HC Wainwright
4/16/2018Roth CapitalSet Price TargetBuy$6.00Low
i
Rating by Jotin Marango at Roth Capital
4/16/2018HC WainwrightSet Price TargetBuy$6.00Low
i
Rating by Joseph Pantginis at HC Wainwright
3/28/2018HC WainwrightSet Price TargetBuy$6.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/7/2018HC WainwrightSet Price TargetBuy$6.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/13/2017HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $6.00High
i
Rating by Joseph Pantginis at HC Wainwright
11/15/2017Canaccord GenuitySet Price TargetBuy$7.00N/A
i
Rating by John Newman at Canaccord Genuity
11/15/2017HC WainwrightSet Price TargetBuy$4.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
10/30/2017HC WainwrightSet Price TargetBuy$4.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
10/23/2017Roth CapitalReiterated RatingBuy ➝ Buy$5.00N/A
i
Rating by J. Marango at Roth Capital
9/7/2017HC WainwrightUpgradeNeutral ➝ Buy$1.00 ➝ $4.00High
i
Rating by Joseph Pantginis at HC Wainwright
6/8/2017HC WainwrightInitiated CoverageHoldHigh
i
Rating by Joseph Pantginis at HC Wainwright
6/8/2017Rodman & RenshawInitiated CoverageNeutral ➝ NeutralHigh
i
5/12/2017Canaccord GenuityReiterated RatingBuy$7.00Low
i
Rating by John Newman at Canaccord Genuity
1/23/2017Canaccord GenuityReiterated RatingBuy$7.00N/A
i
11/16/2016Royal Bank of CanadaLower Price TargetOutperform$18.00 ➝ $12.00N/A
i
10/15/2016Canaccord GenuityReiterated RatingBuy$7.00N/A
i
10/14/2016Roth CapitalReiterated RatingBuy$8.00N/A
i
Rating by Joseph Pantginis at Roth Capital
9/13/2016Royal Bank of CanadaReiterated RatingOutperformN/A
i
6/25/2016Royal Bank of CanadaReiterated RatingOutperform$23.00N/A
i
6/13/2016Royal Bank of CanadaReiterated RatingOutperform$23.00N/A
i
6/13/2016Roth CapitalUpgradeNeutral ➝ Buy$4.00 ➝ $8.00N/A
i
Rating by J. Pantginis at Roth Capital
6/9/2016Canaccord GenuityReiterated RatingBuy$7.00N/A
i
6/9/2016OppenheimerReiterated RatingBuyN/A
i
3/30/2016Canaccord GenuityReiterated RatingBuy$13.00N/A
i
Rating by John Newman at Canaccord Genuity
3/30/2016Royal Bank of CanadaLower Price TargetOutperform$19.00 ➝ $18.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
(Data available from 11/29/2015 forward)
Aptose Biosciences logo
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $6.28
$6.16
$6.40

50 Day Range

MA: $5.38
$4.38
$6.28

52 Week Range

Now: $6.28
$2.43
$9.25

Volume

435,471 shs

Average Volume

905,867 shs

Market Capitalization

$558.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52